- CMS published the premium totals for Medicare on June 21, 2026.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- Medicare negotiates volume discounts on drugs, while lobbying efforts block government cost-trimming.
The pharmaceutical industry is pushing a narrative against the 340B drug pricing program.
1 report, 1 independent
Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The pharmaceutical industry is pushing a narrative against the 340B drug pricing program.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Medicare
US federal health insurance
Related events
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
- Tariffs are introducing uncertainty into the drug market structure.
- Food City adheres to standards set by the American Pharmacists Association and accepts insurance including Medicare Part B.
- Medicare coverage rules restrict access to FDA-approved drugs.
- Finance expert comments on Medicare program value, supported by findings published in JAMA Internal Medicine.